Page 17 - Slide 1
P. 17
Amgen Bone Health Mentoring Program
Monday, October 15, at 11:30am – 2:30pm ◼ Ruth Chris, Minneapolis, MN
1065 LLP2A-Alendronate, a Novel Anabolic Treatment to
Reverse Bone Loss.
Yao W, Guan M, Jia J, et al.
Session: Concurrent Oral Session 11: Osteoporosis -
Treatment (Preclinical) ◼ Saturday , October 13, 03:15
PM - 03:30 PM ◼ Auditorium Room 3/Minneapolis
Convention Center
Results Abstract Information Additional Notes from
Poster/Presentation*
Conclusions ▪ LLP2A-Ale partially prevented trabecular
Implications bone loss induced by estrogen deficiency . Updated/Additional
for Canadian Data, Key Takeaways
▪ MSC + LLP2A-Ale restored lost bone
Practice induced by estrogen deficiency through
increases in osteoblast surface and
mineral apposition rate.
▪ The effects of LLP2A-Ale + transplanted
MSCs were superior to LLP2A-Ale alone,
especially at the cortical bone
▪ As compared to placebo, BFR/BS was
increased by 35% in LLP2A-Ale group and
by 192% in MSC + LLP2A-Ale group.
▪ MSC +LLP2A-Ale treatment increased
cortical bone maximum stress by 8% as
compared to the placebo-treated group.
▪ LLP2A-Ale is a promising option for the
treatment of bone loss related to age and
hormone deficiency.
Discussion Points, Key Takeaways
